« Previous
Next »
The Journal of Urology
Volume 183, Issue 3
, Pages 852-853
, March 2010
Prostate Biopsy: A Risk-Benefit Analysis
References
- . The role of imaging in screening for prostate cancer (A decision analysis perspective). Invest Radiol. 1990;25:591
- . Prostate cancer. In: Urologic Disease in America. National Institutes of Health Publication 07-5512. United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington D. C: United States Government Publishing Office; 2007;p. 76
- Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology. 2009;74:119
- Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379
- Kapoor DA, Klimberg IW, Malek GH et al: Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 2998: 52: 552.
- . Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85:682
- Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998–2007. J Antimicrob Chemother. 2009;64:169
- Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007;99:1395
- PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336
- Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320
PII: S0022-5347(09)03254-6
doi: 10.1016/j.juro.2009.12.063
© 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc All rights reserved.
« Previous
Next »
The Journal of Urology
Volume 183, Issue 3
, Pages 852-853
, March 2010

